2 June 2016 - The TGA has approved Astra Zeneca's lesinurad (Zurampic).

Zurampic has approved by the TGA on 1 June 2016 for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricaemia associated with gout in patients who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.

The FDA approved Zurampic on 22 December 2015.

For more details, go to: http://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia